Spinogenix's Tazbentetol Shows Rapid Cognitive Improvement in Phase 2a Alzheimer's Trial
核心洞察
Tazbentetol (搜索) demonstrated a >2.5 point average increase in cognitive scores within four weeks compared to placebo in mild-to-moderate Alzheimer's patients.
The first-in-class synaptic regenerative therapy showed sustained cognitive improvement through 24 weeks with a favorable safety profile and no severe adverse events.
EEG biomarker analysis revealed significant improvement in AD-related brain activity patterns, including reversal of cortical "slowing" across multiple frequency bands.
Spinogenix (搜索) announced encouraging results from its Phase 2a trial of Tazbentetol (搜索), a first-in-class synaptic regenerative therapy that demonstrated rapid and sustained cognitive improvement in patients with Alzheimer's disease (搜索). The randomized, double-blind, placebo-controlled study enrolled 24 patients in Australia and showed promising efficacy across multiple cognitive measures.
Trial Design and Patient Population
The Phase 2a study (NCT06427668) evaluated Tazbentetol (搜索) in participants with mild-to-moderate Alzheimer's disease (搜索), defined by standardized mini mental status exam (MMSE) scores between 16 and 26. Patients received either 300mg or 150mg of Tazbentetol daily for up to 24 weeks, beginning with a four-week placebo-controlled period. The study's primary endpoints included SMMSE, Clinical Dementia (搜索) Rating Sum of Boxes (CDR-SB), Activities of Daily Living (ADL), and neurophysiological EEG biomarker measures of AD-related brain activity.
Rapid Cognitive Benefits
Results for the 300mg dose, presented at the Clinical Trials on Alzheimer's Disease (搜索) (CTAD) conference on December 4, 2025, demonstrated rapid cognitive gains. Participants displayed evidence of early cognitive benefits, with a >2.5 point average increase in SMMSE within four weeks versus placebo (p < 0.05).
The cognitive improvements proved durable, with sustained improvement observed through the 24-week open-label period across SMMSE, CDR-SB, and ADL outcomes. Notably, scores on the CDR-SB and ADL outcome measures continued to improve over baseline through 40 weeks, suggesting increasing benefit over time.
Neurophysiological Evidence of Synaptic Regeneration
Treatment with 300mg Tazbentetol (搜索) was associated with significant improvement in AD-related brain activity patterns as assessed by EEG. The analysis revealed a reversal of established metrics of cortical "slowing" across multiple frequency bands, providing objective neurophysiological biomarker evidence of synaptic regeneration.
"This Phase 2a study of Tazbentetol (搜索) shows encouraging results for synaptic regeneration as a new treatment paradigm in Alzheimer's," said Professor Bruce Brew, MD, DSc, FRACP, FAAN, neurologist and principal investigator at St. Vincent's Hospital in Sydney, Australia. "These results show Tazbentetol's early potential to deliver rapid and sustained cognitive improvement as measured by SMMSE and CDR-SB."
Safety Profile
Tazbentetol (搜索) demonstrated a favorable safety profile with no severe or treatment-related adverse events. The therapy was well tolerated by participants taking the drug both as a monotherapy and in combination with standard of care therapy.
Mechanism and Therapeutic Approach
Tazbentetol (搜索) is designed to trigger neurons to produce new glutamatergic synapses (搜索) and restore cognitive, motor, and other functions. The rapid and sustained effects observed in the clinical trial are consistent with findings from a NIH-supported, published Alzheimer's mouse model study where synapse loss in the hippocampus was improved within weeks of daily dosing (Trujillo-Estrada et al, 2021).
"We are highly encouraged by these results, which show the potential impact that a synaptic regenerative therapy can play in helping restore cognitive function in those with Alzheimer's disease (搜索)," said Dr. Stella Sarraf, Chief Executive Officer and Founder of Spinogenix (搜索). "With our IND cleared in the U.S., we are looking forward to continuing global development of this first-in-class, and potentially transformative investigational treatment."
Clinical Context and Development Pipeline
Alzheimer's disease (搜索) is the most common cause of dementia (搜索), accounting for 60-70% of cases worldwide. Loss of synapses occurs very early in the disease's progression and is a major driver of cognitive decline and memory loss. Tazbentetol (搜索) represents a new class of regenerative therapeutics that can be used in combination with standard-of-care cholinesterase inhibitors (搜索), as well as recently approved antibody therapies targeting amyloid beta (搜索).
The FDA cleared Spinogenix (搜索)'s Investigational New Drug (IND) application for Tazbentetol (搜索) for the treatment of Alzheimer's disease (搜索) earlier this year. Beyond Alzheimer's, Tazbentetol is being evaluated as an investigational therapeutic in ALS (搜索) (NCT05882695) and Schizophrenia (搜索) (NCT06442462), reflecting its potential across multiple neurodegenerative and neuropsychiatric conditions.